



# CERTIFICATE OF ANALYSIS




## Product Details

Product name:	Anti-BCMA & CD3 Reference Antibody (Elranatamab)	Lot.No.:	P262500
Target:	TNFRSF17 / BCMA / CD269, CD3	Catalog:	CHBA010
Target Accession:	Q02223 & P07766	Concentration :	1 mg/mL
Clonality:	Bispecific	Isotype:	IgG-like
Reactivity:	Human	Molecular Weight (kDa) :	145.44 kDa
Application:	Kinetics (SPR), ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0   Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	Upon receipt, store immediately at -20°C or lower for 24 months. Store aliquots at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.	Purification:	Protein A


# Data

## MASS




The detected molecular weight of Anti-BCMA & CD3 Reference Antibody (Elranatamab) is 145.21 kDa. The mass spectrum exhibits two peaks, suggesting the possible presence of a homodimer.

## Purity: SDS-PAGE




Anti-BCMA & CD3 Reference Antibody (Elranatamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

## Purity: SEC-HPLC



The purity of Anti-BCMA & CD3 Reference Antibody (Elranatamab) is 99.34%, determined by SEC-HPLC.


## ELISA



Elranatamab-Bcmm bound to BCMA protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP), and read OD450. As shown in fig, Elranatamab-Bcmm bound to huBCMA-ECD-His, and the EC50 was 0.055 nM.


The products are for research use only. Not for use in diagnostic procedures.

## Bioactivity: FACS




Elranatamab-Bcmm bound to huBCMA-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE), and test by flow cytometry. As shown in fig, Elranatamab-Bcmm bound to huBCMA-HEK293 cells, and the EC50 was 1.263 nM.

## Bioactivity: FACS



Elranatamab-Bcmm bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE), and test by flow cytometry. As shown in fig, Elranatamab-Bcmm bound to huCD3e-jurkat cells, and the EC50 was 64.990 nM.

## Function: Luciferase



Co-incubation of Elranatamab-Bcmm with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Elranatamab-Bcmm was able to activate the NF-AT signaling pathway, and the EC50 was 0.081 nM.

The products are for research use only. Not for use in diagnostic procedures.